Several drugs, such as gefitinib and erlotinib, are specific for EGFR, whereas others (lapatinib ... who did not respond to at least one prior chemotherapy. In November 2005, erlotinib was ...

the improvement in quality of life and the assurance of drug exposure, considering that 30–41% of patients with EGFR mutations randomly assigned to first-line chemotherapy in randomized clinical ...

In this video, Xiuning Le, MD, PhD, discusses how she approaches putting together a treatment plan for a patient with EGFR-mutated lung cancer.

Priority review aims for faster FDA action on drugs that significantly improve ... sunvozertinib versus platinum-based doublet chemotherapy among participants with locally advanced or metastatic NSCLC ...

The US regulator has approved the drug after a priority review on the strength of data from the FLAURA 2 study showing that the combination of EGFR inhibitor Tagrisso (osimertinib) and chemo cut ...

In this video, Xiuning Le, MD, PhD, discusses how the definition of EGFR-mutated lung cancer has expanded in recent years.

Key opinion leaders discusses strategies for handling gastrointestinal side effects in patients taking osimertinib, including ...

A phase 2 trial finds that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy.

In December, Datroway was approved in Japan to treat patients with a type of breast cancer who had previously received chemotherapy. In a late-stage trial, the drug slowed disease progression in ...

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

in which treatment with the drug after surgery reduced the relative risk of disease recurrence or death by 83% compared to placebo in patients with stage 2 to 3A EGFR-mutated NSCLC. Survival without ...